www.semnurpharma.com Open in urlscan Pro
2607:f1c0:100f:f000::217  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Semnurpharma - Getting back to normal


GETTING BACK TO NORMAL

 * About
   * Overview
   * Leadership Team
   * Board of Directors
   * Our Culture
 * Partners
 * Chronic Back Pain
   * Chronic Back Pain
   * SP-102 (SEMDEXA™)
   * About our Studies
     * Phase 3 C.L.E.A.R. Study
     * Phase 2 Repeat Dose Study – SP102-03
     * Phase 1 PK/PD and Safety Study – SP-102
     * Pre-Clinical Study – SP-102
 * Science
   * Technology
   * Publications
 * Investors
   * Investor Overview
   * Presentation
   * News and Events
   * SEC Filings
   * Analyst Coverage
   * Contact Investor Relations
 * Join Our Team
 * Contact Us

Toggle menu



SEMNURPHARMA - GETTING BACK TO NORMAL


GETTING BACK TO NORMAL

 * About
   * Overview
   * Leadership Team
   * Board of Directors
   * Our Culture
 * Partners
 * Chronic Back Pain
   * Chronic Back Pain
   * SP-102 (SEMDEXA™)
   * About our Studies
     * Phase 3 C.L.E.A.R. Study
     * Phase 2 Repeat Dose Study – SP102-03
     * Phase 1 PK/PD and Safety Study – SP-102
     * Pre-Clinical Study – SP-102
 * Science
   * Technology
   * Publications
 * Investors
   * Investor Overview
   * Presentation
   * News and Events
   * SEC Filings
   * Analyst Coverage
   * Contact Investor Relations
 * Join Our Team
 * Contact Us

Toggle menu




HOME


SECOND MOST COMMON CAUSE


Low back pain is second most common cause of disability in the US.


OVER 80%


Of people will experience an episode of this pain at some point in their lives.


12+ MILLION


Procedures of Epidural Steroid Injections in US


MOST COMMON REASONS


Most common reasons for low back pain are disc injuries, sciatica, lifting heavy
objects, or some other non-specific back injury.


WHO WE ARE


A BIOPHARMACEUTICAL COMPANY FOCUSED ON THE CLINICAL AND COMMERCIAL DEVELOPMENT
OF NOVEL NON-OPIOID PRODUCTS THAT MEET THE NEEDS OF PAIN MANAGEMENT
PRACTITIONERS AND THEIR PATIENTS.

Back pain affects most adults, causes disability for some, and is a common
reason for seeking healthcare. In the United States, opioid prescription for low
back pain has increased, and opioids are now the most commonly prescribed drug
class. More than half of regular opioid users report back pain. Rates of opioid
prescribing in the US and Canada are two to three times higher than in most
European countries.

Semnur’s lead program, SP-102 (SEMDEXA™), is the first non-opioid novel
injectable corticosteroid gel formulation for patients with moderate to severe
chronic radicular pain/sciatica, containing no preservatives, surfactants,
solvents, or particulates.

→ Read More



ABOUT THE STUDY


LEARN MORE ABOUT OUR CLINICAL STUDY

Opioid prescriptions account for up to 60 percent of the chronic pain market and
carry a well-known risk of abuse and misuse, underscoring the need for
alternative pain therapies without the medical and societal challenges.

THE PHASE 3 C.L.E.A.R. CLINICAL RESEARCH STUDY

was conducted at sites throughout the U.S. The purpose of the Study was to
evaluate SP-102 (SEMDEXA™) for the relief of sciatica. SP-102 (SEMDEXA™) is a
novel, non-opioid injectable gel formulation intended for the treatment of
lumbar radicular pain, commonly known as Sciatica.

→ Read More





PUBLICATIONS

AMERICAN SOCIETY OF INTERVENTIONAL PAIN PHYSICIANS, ASIPP 2022


RESULTS FROM A PIVOTAL PHASE 3, DB, R, PLACEBO-CONTROLLED, MULTICENTER TRIAL OF
SP-102, A NOVEL DEXAMETHASONE INJECTABLE FORMULATION, FOR THE TREATMENT OF
PATIENTS WITH LUMBOSACRAL RADICULOPATHY (SCIATICA)

PAIN JOURNAL 2024


A RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF LONG-ACTING DEXAMETHASONE VISCOUS GEL
DELIVERED BY TRANSFORAMINAL INJECTION FOR LUMBOSACRAL RADICULAR PAIN

Read All Publications

PRESENTATION


DOWNLOAD HERE THE SEMNUR PHARMACEUTICALS, INC. CORPORATE PRESENTATION






 

 * Overview
 * Partners
 * Our Culture
 * Product
 * Publications
 * Join Our Team
 * Presentation
 * Contact Us


CONNECT, FOLLOW AND HAVE A CONVERSATION WITH US

 * 
 * 
 * 
 * 

 * 960 San Antonio Road, Palo Alto, CA, 94303
 * (650) 516-4310
 * info@semnurpharma.com

Privacy Policy | Terms of Use | © 2024 All rights reserved.

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding
Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of
a Merger Agreement for a proposed Business Combination, Provides for a
Pre-Transaction Equity Value of Semnur of $2.5 Billion.

Check Our Press Release









X

… heavy objects, or some other non-specific back injury.

Reference:
@srinipillay 2016:
https://www.health.harvard.edu/blog/psychology-low-back-pain-201604259537

X

Reference:
@srinipillay 2016:
https://www.health.harvard.edu/blog/psychology-low-back-pain-201604259537

X

Reference:
@srinipillay
2016:https://www.health.harvard.edu/blog/psychology-low-back-pain-201604259537

X

The overall estimated number of epidural steroid injection (ESI) procedures in
the U.S. is approximately 12.1 million across all Medicare and private coverage
patients, with lumbar radiculopathy/sciatica procedures comprising approximately
88% of all ESIs administered, according to a proprietary study by Syneos Health.
*

References:
*  Syneos Health

X